About Boston Scientific (NYSE:BSX)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:BSX
CUSIP10113710
Phone508-683-4000
Debt
Debt-to-Equity Ratio0.54%
Current Ratio0.68%
Quick Ratio0.49%
Price-To-Earnings
Trailing P/E Ratio22.93
Forward P/E Ratio21.09
P/E Growth2.09
Sales & Book Value
Annual Sales$9.05 billion
Price / Sales4.39
Cash Flow$1.8957 per share
Price / Cash15.24
Book Value$5.11 per share
Price / Book5.65
Profitability
EPS (Most Recent Fiscal Year)$1.26
Net Income$105 million
Net Margins1.15%
Return on Equity24.27%
Return on Assets9.48%
Miscellaneous
Employees29,000
Outstanding Shares1,374,910,000
Boston Scientific (NYSE:BSX) Frequently Asked Questions
What is Boston Scientific's stock symbol?
Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."
How were Boston Scientific's earnings last quarter?
Boston Scientific (NYSE:BSX) posted its earnings results on Thursday, February, 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.34. The medical equipment provider had revenue of $2.41 billion for the quarter, compared to analyst estimates of $2.39 billion. Boston Scientific had a return on equity of 24.27% and a net margin of 1.15%. The firm's quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.30 earnings per share. View Boston Scientific's Earnings History.
When is Boston Scientific's next earnings date?
What guidance has Boston Scientific issued on next quarter's earnings?
Boston Scientific issued an update on its FY18 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of $1.35-1.39 for the period, compared to the Thomson Reuters consensus estimate of $1.38. The company issued revenue guidance of $9.650-$9.800 billion, compared to the consensus revenue estimate of $9.60 billion.Boston Scientific also updated its Q1 guidance to $0.30-0.32 EPS.
What price target have analysts set for BSX?
19 brokerages have issued 1-year target prices for Boston Scientific's stock. Their predictions range from $27.00 to $35.00. On average, they expect Boston Scientific's share price to reach $31.3684 in the next year. View Analyst Ratings for Boston Scientific.
What are Wall Street analysts saying about Boston Scientific stock?
Here are some recent quotes from research analysts about Boston Scientific stock:
- 1. According to Zacks Investment Research, "Despite back-to-back hurricances, Boston Scientific managed to registered solid third-quarter show. An improving foreign exchange scenario has also started to contribute to the company’s overall top line performance. The raised guidance is indicative of this bullish trend to continue through the rest of 2017. The company is leaving no stone unturned to strengthen its core business and invest more in global markets. Among the recent developments, worth mentioning is the acquisition of Apama Medical, in the field of atrial fibrillation. On the flip side, Boston Scientific's unimpressive pacemaker performance within the core CRM continues remains a drag. This apart, based on the recent announcement, we believe further delay in relaunch of the earlier-recalled Lotus range of heart devices is expected to hamper sales in 2018 too. In the past three months, Boston Scientific has been trading below the broader industry." (1/30/2018)
- 2. Canaccord Genuity analysts commented, "We reiterate our BUY rating and $35 year-end target price on shares of BSX. Our key takeaways from our meeting last week with senior management in San Francisco (as well as incremental tidbits we gleaned over the weekend at the North American Neuromodulation Society (NANS) conference in Vegas) support our general hypothesis on the stock: We expect BSX to deliver top- and bottom-line growth rates above the large-cap medical device peer group average over the 2018-2020 timeframe." (1/17/2018)
- 3. Jefferies Group LLC analysts commented, "We are re-establishing estimates, a Buy rating and $14.00 PT for Flex Pharma. Flex is developing FLX-787, an innovative anti-cramp drug in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) and multiple sclerosis (MS). We believe CMT , on which we base our PT , has the highest chance of success. We anticipate Ph2 data in 1Q’18 (MS) and 3Q’18 (ALS, CMT). In 2Q’16, Flex launched HOTSHOT , a consumer beverage for exercise- associated muscle cramps that works via the same mechanisms as FLX-787." (9/7/2017)
- 4. Needham & Company LLC analysts commented, "BSX beat consensus 1Q17 revenue but missed consensus EPS due to expense associated with the Lotus withdrawal. Management raised its revenue guidance but maintained its EPS guidance for 2017. BSX’s organic revenue growth slowed slightly to 9% in 1Q17 from 10% in 4Q16 despite facing a more difficult comp. MedSurg growth accelerated and offset slower Cardiovascular growth as BSX lapped the US Synergy launch. Margins were below expectations with BSX’s gross margin down 170 bps Y/Y and operating margin down 210 bps Y/Y but this was mostly due to the impact of the Lotus withdrawal." (4/27/2017)
Who are some of Boston Scientific's key competitors?
Some companies that are related to Boston Scientific include Becton Dickinson (BDX), Stryker (SYK), Fresenius (FSNUY), Baxter International (BAX), ResMed (RMD), Abiomed (ABMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Globus Medical (GMED), Cantel Medical (CMD), Penumbra (PEN), Haemonetics (HAE), Nevro (NVRO), NuVasive (NUVA) and Merit Medical Systems (MMSI).
Who are Boston Scientific's key executives?
Boston Scientific's management team includes the folowing people:
- Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 53)
- Mr. Daniel J. Brennan, Exec. VP & CFO (Age 52)
- Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 54)
- Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 45)
- Mr. Edward F. Mackey, Exec. VP of Operations (Age 55)
Has Boston Scientific been receiving favorable news coverage?
News coverage about BSX stock has trended somewhat positive this week, according to Accern. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Boston Scientific earned a media sentiment score of 0.12 on Accern's scale. They also assigned news headlines about the medical equipment provider an impact score of 48.56 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Boston Scientific?
Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Boston Scientific's stock price today?
One share of BSX stock can currently be purchased for approximately $28.89.
How big of a company is Boston Scientific?
Boston Scientific has a market capitalization of $39.68 billion and generates $9.05 billion in revenue each year. The medical equipment provider earns $105 million in net income (profit) each year or $1.26 on an earnings per share basis. Boston Scientific employs 29,000 workers across the globe.
How can I contact Boston Scientific?
Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]
MarketBeat Community Rating for Boston Scientific (BSX)
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe BSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Boston Scientific (NYSE:BSX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
19 Wall Street analysts have issued ratings and price targets for Boston Scientific in the last 12 months. Their average twelve-month price target is $31.3684, suggesting that the stock has a possible upside of 8.58%. The high price target for BSX is $35.00 and the low price target for BSX is $27.00. There are currently 4 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
Consensus Rating: | Buy | Buy | Buy | Buy |
Consensus Rating Score: | 2.84 | 2.84 | 2.83 | 2.76 |
Ratings Breakdown: | 0 Sell Rating(s) 4 Hold Rating(s) 14 Buy Rating(s) 1 Strong Buy Rating(s) | 0 Sell Rating(s) 4 Hold Rating(s) 14 Buy Rating(s) 1 Strong Buy Rating(s) | 0 Sell Rating(s) 4 Hold Rating(s) 13 Buy Rating(s) 1 Strong Buy Rating(s) | 0 Sell Rating(s) 4 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s) |
Consensus Price Target: | $31.3684 | $31.0556 | $30.8750 | $30.6071 |
Price Target Upside: | 8.58% upside | 11.31% upside | 13.30% upside | 4.00% upside |
Boston Scientific (NYSE:BSX) Consensus Price Target History

Boston Scientific (NYSE:BSX) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Boston Scientific (NYSE:BSX) Dividend History by Quarter
Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
---|
(Data available from 1/1/2013 forward)
Boston Scientific (NYSE BSX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.73%
Institutional Ownership Percentage: 91.05%
Boston Scientific (NYSE BSX) Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
4/2/2018 | David A Pierce | EVP | Sell | 5,000 | $27.22 | $136,100.00 | | |
3/20/2018 | John Bradley Sorenson | SVP | Sell | 2,200 | $27.63 | $60,786.00 | 34,636 | |
3/19/2018 | Daniel J Brennan | CFO | Sell | 60,209 | $27.87 | $1,678,024.83 | 299,644 | |
3/14/2018 | Kevin J Ballinger | EVP | Sell | 42,803 | $28.32 | $1,212,180.96 | | |
3/5/2018 | John Bradley Sorenson | SVP | Sell | 1,950 | $27.43 | $53,488.50 | | |
2/28/2018 | David A Pierce | SVP | Sell | 4,508 | $27.54 | $124,150.32 | | |
2/21/2018 | David A Pierce | SVP | Sell | 16,286 | $27.00 | $439,722.00 | | |
2/9/2018 | Maulik Nanavaty | SVP | Sell | 15,568 | $25.38 | $395,115.84 | | |
2/7/2018 | Joseph Michael Fitzgerald | EVP | Sell | 85,227 | $26.48 | $2,256,810.96 | | |
2/1/2018 | David A Pierce | SVP | Sell | 5,152 | $27.43 | $141,319.36 | 29,353 | |
1/11/2018 | David A Pierce | SVP | Sell | 8,763 | $27.74 | $243,085.62 | 24,201 | |
1/9/2018 | David A Pierce | SVP | Sell | 5,152 | $27.00 | $139,104.00 | 38,116 | |
12/29/2017 | Michael P Phalen | EVP | Sell | 15,835 | $25.25 | $399,833.75 | | |
12/29/2017 | Michael P. Phalen | EVP | Sell | 15,835 | $25.25 | $399,833.75 | | |
12/1/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $26.04 | $260,400.00 | 154,681 | |
12/1/2017 | Valley Gold Master Fund L Sun | Insider | Buy | 27,431 | $0.44 | $12,069.64 | | |
11/29/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $26.66 | $413,230.00 | | |
11/28/2017 | Valley Gold Master Fund L Sun | Insider | Buy | 408,006 | $0.45 | $183,602.70 | | |
11/1/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $28.22 | $282,200.00 | 164,681 | |
10/30/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $28.42 | $440,510.00 | | |
10/4/2017 | Supratim Bose | EVP | Sell | 347,137 | $29.12 | $10,108,629.44 | | |
10/2/2017 | Timothy A Pratt | EVP | Sell | 11,061 | $29.24 | $323,423.64 | 174,681 | |
9/29/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $28.72 | $445,160.00 | | |
9/1/2017 | Timothy A Pratt | EVP | Sell | 10,104 | $27.46 | $277,455.84 | 185,742 | |
8/31/2017 | Maulik Nanavaty | SVP | Sell | 57,031 | $27.28 | $1,555,805.68 | | |
8/30/2017 | Maulik Nanavaty | SVP | Sell | 27,031 | $27.08 | $731,999.48 | | |
8/29/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $26.87 | $416,485.00 | | |
8/3/2017 | Wendy Carruthers | SVP | Sell | 12,433 | $26.75 | $332,582.75 | | |
8/2/2017 | John Bradley Sorenson | SVP | Sell | 7,900 | $26.37 | $208,323.00 | 21,680 | |
8/1/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $26.67 | $266,700.00 | 195,846 | |
7/31/2017 | John Bradley Sorenson | SVP | Sell | 2,100 | $27.15 | $57,015.00 | 18,880 | |
7/31/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $27.13 | $420,515.00 | | |
7/11/2017 | Daniel J Brennan | CFO | Sell | 92,158 | $27.48 | $2,532,501.84 | 235,421 | |
7/3/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $27.87 | $278,700.00 | 205,846 | |
6/29/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $28.02 | $434,310.00 | | |
6/9/2017 | David A Pierce | SVP | Sell | 13,562 | $28.00 | $379,736.00 | 33,701 | |
6/2/2017 | David A Pierce | SVP | Sell | 2,972 | $27.70 | $82,324.40 | 28,572 | |
6/1/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $27.13 | $271,300.00 | 215,846 | |
5/30/2017 | Michael P. Phalen | EVP | Sell | 15,500 | $27.25 | $422,375.00 | | |
5/17/2017 | Kevin J. Ballinger | EVP | Sell | 28,864 | $26.14 | $754,504.96 | | |
5/1/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $26.37 | $263,700.00 | 225,846 | |
4/26/2017 | David A Pierce | SVP | Sell | 10,250 | $26.00 | $266,500.00 | 35,850 | |
4/26/2017 | Michael P. Phalen | EVP | Sell | 34,773 | $26.00 | $904,098.00 | | |
4/10/2017 | John Bradley Sorenson | SVP | Sell | 2,950 | $24.66 | $72,747.00 | 20,980 | |
4/3/2017 | Timothy A Pratt | EVP | Sell | 10,000 | $24.87 | $248,700.00 | 235,846 | |
3/29/2017 | Michael P. Phalen | EVP | Sell | 79,045 | $24.55 | $1,940,554.75 | | |
3/3/2017 | David A Pierce | SVP | Sell | 25,012 | $25.01 | $625,550.12 | 25,600 | |
3/3/2017 | Timothy A Pratt | EVP | Sell | 23,540 | $25.01 | $588,735.40 | 245,846 | |
2/27/2017 | David A Pierce | SVP | Sell | 3,417 | $24.84 | $84,878.28 | 34,267 | |
2/27/2017 | Timothy A Pratt | EVP | Sell | 4,832 | $24.84 | $120,026.88 | 248,758 | |
2/7/2017 | Keith D Dawkins | EVP | Sell | 80,783 | $25.21 | $2,036,539.43 | 75,864 | |
1/9/2017 | David A Pierce | SVP | Sell | 10,232 | $22.24 | $227,559.68 | 25,600 | |
1/9/2017 | Timothy A Pratt | EVP | Sell | 6,195 | $22.24 | $137,776.80 | 231,273 | |
12/1/2016 | Timothy A Pratt | EVP | Sell | 26,726 | $20.48 | $547,348.48 | 260,430 | |
8/11/2016 | John Bradley Sorenson | SVP | Sell | 2,500 | $23.90 | $59,750.00 | 12,615 | |
8/1/2016 | Michael F Mahoney | CEO | Sell | 44,400 | $24.44 | $1,085,136.00 | 1,388,177 | |
8/1/2016 | Timothy A Pratt | EVP | Sell | 24,000 | $24.46 | $587,040.00 | 287,495 | |
7/20/2016 | David A Pierce | SVP | Sell | 2,480 | $24.03 | $59,594.40 | 28,080 | |
7/20/2016 | Michael P. Phalen | EVP | Sell | 35,000 | $24.03 | $841,050.00 | | |
6/1/2016 | Michael F Mahoney | CEO | Sell | 100,000 | $22.69 | $2,269,000.00 | 1,532,577 | |
6/1/2016 | Timothy A Pratt | EVP | Sell | 24,229 | $22.66 | $549,029.14 | 301,724 | |
5/11/2016 | John Bradley Sorenson | SVP | Sell | 2,800 | $22.15 | $62,020.00 | 15,115 | |
5/10/2016 | Keith D Dawkins | EVP | Sell | 80,000 | $22.15 | $1,772,000.00 | 150,227 | |
5/6/2016 | Jeffrey B Mirviss | SVP | Sell | 24,659 | $21.94 | $541,018.46 | 71,975 | |
5/3/2016 | Joseph Michael Fitzgerald | EVP | Sell | 79,960 | $21.81 | $1,743,927.60 | 92,020 | |
5/2/2016 | Michael F Mahoney | CEO | Sell | 100,000 | $22.12 | $2,212,000.00 | 1,632,577 | |
5/2/2016 | Timothy A Pratt | EVP | Sell | 24,000 | $21.93 | $526,320.00 | 308,724 | |
4/27/2016 | Kevin J Ballinger | SVP | Sell | 111,807 | $21.62 | $2,417,267.34 | 83,600 | |
4/27/2016 | Timothy A Pratt | EVP | Sell | 39,927 | $21.40 | $854,437.80 | 291,724 | |
4/4/2016 | Jeffrey B Mirviss | SVP | Sell | 18,422 | $19.00 | $350,018.00 | 96,634 | |
4/1/2016 | Michael F Mahoney | CEO | Sell | 100,000 | $18.90 | $1,890,000.00 | 1,732,577 | |
4/1/2016 | Timothy A Pratt | EVP | Sell | 24,000 | $18.73 | $449,520.00 | 355,651 | |
3/11/2016 | Kevin J Ballinger | SVP | Sell | 16,705 | $18.00 | $300,690.00 | 46,970 | |
3/8/2016 | Karen Prange | SVP | Sell | 14,747 | $17.27 | $254,680.69 | 38,395 | |
3/2/2016 | Michael P. Phalen | EVP | Sell | 10,665 | $17.17 | $183,118.05 | 89,309 | |
3/1/2016 | Michael F Mahoney | CEO | Sell | 100,000 | $16.96 | $1,696,000.00 | 1,832,577 | |
3/1/2016 | Timothy A Pratt | EVP | Sell | 15,068 | $16.97 | $255,703.96 | 338,651 | |
2/29/2016 | Kevin J. Ballinger | SVP | Sell | 2,114 | $17.17 | $36,297.38 | | |
2/29/2016 | Michael P. Phalen | EVP | Sell | 1,819 | $17.19 | $31,268.61 | | |
2/25/2016 | Daniel J Brennan | CFO | Sell | 103,211 | $17.22 | $1,777,293.42 | 202,659 | |
2/25/2016 | Kevin J. Ballinger | SVP | Sell | 1,903 | $17.48 | $33,264.44 | | |
2/25/2016 | Michael P. Phalen | EVP | Sell | 34,106 | $17.28 | $589,351.68 | | |
2/17/2016 | Kevin J. Ballinger | SVP | Sell | 7,616 | $17.37 | $132,289.92 | | |
2/12/2016 | Charles J Dockendorff | Director | Buy | 30,000 | $16.49 | $494,700.00 | 41,598 | |
2/8/2016 | Karen Prange | SVP | Sell | 6,216 | $16.05 | $99,766.80 | 23,647 | |
1/8/2016 | Timothy A Pratt | EVP | Sell | 7,160 | $17.67 | $126,517.20 | 303,776 | |
1/7/2016 | Kevin J Ballinger | SVP | Sell | 19,059 | $17.73 | $337,916.07 | 30,323 | |
1/5/2016 | Jeffrey B Mirviss | SVP | Sell | 9,953 | $18.00 | $179,154.00 | 82,535 | |
12/1/2015 | Timothy A. Pratt | EVP | Sell | 24,000 | $18.43 | $442,320.00 | 282,295 | |
11/16/2015 | Ernest Mario | Director | Sell | 125,000 | $17.63 | $2,203,750.00 | 86,032 | |
11/9/2015 | John Bradley Sorenson | SVP | Sell | 4,469 | $18.68 | $83,480.92 | 5,605 | |
11/9/2015 | Joseph Michael Fitzgerald | EVP | Sell | 26,220 | $18.58 | $487,167.60 | 103,925 | |
11/5/2015 | Timothy A Pratt | EVP | Sell | 19,598 | $19.00 | $372,362.00 | 289,295 | |
10/28/2015 | Jeffrey B Mirviss | SVP | Sell | 9,492 | $18.00 | $170,856.00 | 81,262 | |
10/28/2015 | Timothy A Pratt | EVP | Sell | 3,500 | $18.00 | $63,000.00 | 315,893 | |
10/5/2015 | Timothy A Pratt | EVP | Sell | 3,500 | $17.34 | $60,690.00 | 319,393 | |
10/1/2015 | Timothy A. Pratt | EVP | Sell | 17,000 | $16.33 | $277,610.00 | 322,893 | |
8/21/2015 | John E Abele | Director | Buy | 200,000 | $16.77 | $3,354,000.00 | 92,983 | |
8/19/2015 | John E Abele | Director | Buy | 200,000 | $17.48 | $3,496,000.00 | 92,983 | |
8/17/2015 | John E Abele | Director | Buy | 100,000 | $17.50 | $1,750,000.00 | | |
7/7/2015 | Karen Prange | SVP | Sell | 17,456 | $17.66 | $308,272.96 | | |
5/29/2015 | Maulik Nanavaty | SVP | Sell | 71,558 | $18.52 | $1,325,254.16 | | |
5/28/2015 | Wendy Carruthers | SVP | Sell | 42,281 | $17.91 | $757,252.71 | | |
5/18/2015 | Ernest Mario | Director | Sell | 50,000 | $18.09 | $904,500.00 | | |
5/14/2015 | John E Sununu | Director | Sell | 10,000 | $17.87 | $178,700.00 | | |
5/11/2015 | John Bradley Sorenson | SVP | Sell | 8,735 | $17.49 | $152,775.15 | | |
3/20/2015 | David A Pierce | SVP | Sell | 18,050 | $18.00 | $324,900.00 | | |
3/20/2015 | Michael P Phalen | EVP | Sell | 46,085 | $17.94 | $826,764.90 | | |
3/16/2015 | Michael P Phalen | EVP | Sell | 30,022 | $17.18 | $515,777.96 | | |
3/13/2015 | John Bradley Sorenson | SVP | Sell | 3,830 | $16.84 | $64,497.20 | | |
3/9/2015 | David A Pierce | SVP | Sell | 2,561 | $16.54 | $42,358.94 | | |
3/3/2015 | David A Pierce | SVP | Sell | 8,983 | $16.79 | $150,824.57 | | |
3/3/2015 | Michael P Phalen | EVP | Sell | 12,768 | $16.79 | $214,374.72 | | |
2/27/2015 | David A Pierce | SVP | Sell | 19,046 | $16.80 | $319,972.80 | | |
2/27/2015 | Michael P Phalen | EVP | Sell | 1,819 | $16.80 | $30,559.20 | | |
2/19/2015 | David A Pierce | SVP | Sell | 11,958 | $16.46 | $196,828.68 | | |
2/19/2015 | Michael P Phalen | EVP | Sell | 13,188 | $16.44 | $216,810.72 | | |
2/10/2015 | Joseph Michael Fitzgerald | EVP | Sell | 61,208 | $14.66 | $897,309.28 | | |
2/9/2015 | David A Pierce | SVP | Sell | 5,000 | $14.66 | $73,300.00 | | |
2/6/2015 | Kevin J Ballinger | SVP | Sell | 21,408 | $15.06 | $322,404.48 | | |
1/20/2015 | Michael P Phalen | EVP | Sell | 10,000 | $14.54 | $145,400.00 | | |
1/8/2015 | David A Pierce | SVP | Sell | 18,612 | $14.31 | $266,337.72 | | |
1/8/2015 | Michael P Phalen | EVP | Sell | 27,589 | $14.31 | $394,798.59 | | |
1/5/2015 | Michael P Phalen | EVP | Sell | 10,000 | $13.75 | $137,500.00 | | |
12/10/2014 | Karen Prange | SVP | Sell | 19,753 | $12.64 | $249,677.92 | | |
12/8/2014 | David A Pierce | SVP | Sell | 5,000 | $12.90 | $64,500.00 | | |
12/1/2014 | Ernest Mario | Director | Sell | 10,000 | $12.96 | $129,600.00 | | |
11/28/2014 | Michael F Mahoney | CEO | Buy | 11,700 | $12.89 | $150,813.00 | | |
11/10/2014 | Edward J Ludwig | Director | Buy | 10,000 | $13.38 | $133,800.00 | | |
11/5/2014 | John E Sununu | Director | Sell | 8,997 | $13.38 | $120,379.86 | | |
11/3/2014 | Ernest Mario | Director | Sell | 10,000 | $13.30 | $133,000.00 | | |
10/8/2014 | Ernest Mario | Director | Sell | 10,000 | $12.06 | $120,600.00 | | |
9/2/2014 | Ernest Mario | Director | Sell | 10,000 | $12.60 | $126,000.00 | | |
8/15/2014 | Michael P Phalen | EVP | Sell | 11,471 | $12.58 | $144,305.18 | | |
8/1/2014 | Ernest Mario | Director | Sell | 10,000 | $12.58 | $125,800.00 | | |
7/30/2014 | David A Pierce | SVP | Sell | 157 | $12.97 | $2,036.29 | | |
7/15/2014 | Michael P Phalen | EVP | Sell | 67,500 | $13.04 | $880,200.00 | | |
7/1/2014 | Ernest Mario | Director | Sell | 10,000 | $12.95 | $129,500.00 | | |
6/16/2014 | Michael P Phalen | EVP | Sell | 13,500 | $13.02 | $175,770.00 | | |
6/2/2014 | Ernest Mario | Director | Sell | 10,000 | $12.88 | $128,800.00 | | |
5/15/2014 | Michael Phalen | EVP | Sell | 13,500 | $12.76 | $172,260.00 | 127,486 | |
5/1/2014 | Ernest Mario | Director | Sell | 10,000 | $12.58 | $125,800.00 | 317,855 | |
4/15/2014 | Michael Phalen | EVP | Sell | 13,500 | $13.25 | $178,875.00 | 127,486 | |
4/1/2014 | Ernest Mario | Director | Sell | 10,000 | $13.55 | $135,500.00 | 327,855 | |
3/17/2014 | Michael Phalen | EVP | Sell | 13,500 | $13.05 | $176,175.00 | 127,486 | |
3/6/2014 | David Pierce | SVP | Sell | 5,316 | $13.44 | $71,447.04 | 43,161 | |
3/6/2014 | Michael Phalen | EVP | Sell | 7,281 | $13.44 | $97,856.64 | 127,486 | |
2/27/2014 | David Pierce | SVP | Sell | 2,057 | $13.29 | $27,337.53 | 47,990 | |
2/27/2014 | Michael Phalen | EVP | Sell | 3,166 | $13.29 | $42,076.14 | 130,848 | |
2/21/2014 | David Pierce | SVP | Sell | 3,199 | $13.22 | $42,290.78 | 25,600 | |
2/21/2014 | Michael Phalen | EVP | Sell | 3,222 | $13.22 | $42,594.84 | 84,300 | |
2/18/2014 | Michael Phalen | EVP | Sell | 13,500 | $13.30 | $179,550.00 | 87,522 | |
2/13/2014 | Kristina Johnson | Director | Sell | 18,000 | $13.01 | $234,180.00 | 3,124 | |
2/6/2014 | Ernest Mario | Director | Sell | 17,104 | $12.80 | $218,931.20 | 347,855 | |
2/3/2014 | Ernest Mario | Director | Sell | 10,000 | $13.19 | $131,900.00 | 364,959 | |
1/6/2014 | Ernest Mario | Director | Sell | 10,000 | $12.50 | $125,000.00 | 374,959 | |
12/26/2013 | Ernest Mario | Director | Sell | 10,000 | $12.06 | $120,600.00 | 384,959 | |
11/26/2013 | Jeffrey Capello | CFO | Sell | 85,106 | $11.82 | $1,005,952.92 | 109,042 | |
11/11/2013 | Jeffrey Mirviss | SVP | Sell | 26,000 | $11.91 | $309,660.00 | 39,190 | |
8/29/2013 | Jeffrey Capello | CFO | Sell | 525,000 | $10.68 | $5,607,000.00 | 147,447 | |
8/16/2013 | Joseph Michael Fitzgerald | SVP | Sell | 9,202 | $11.02 | $101,406.04 | 93,191 | |
8/14/2013 | Kevin Ballinger | SVP | Sell | 38,171 | $11.28 | $430,568.88 | 73,519 | |
5/31/2013 | Jeffrey B Mirviss | SVP | Sell | 10,941 | $9.37 | $102,517.17 | | |
5/30/2013 | Wendy Carruthers | SVP | Sell | 25,001 | $9.16 | $229,009.16 | | |
5/29/2013 | Nelda J Connors | Director | Sell | 24,116 | $9.17 | $221,143.72 | | |
5/6/2013 | Ernest Mario | Director | Buy | 30,000 | $7.76 | $232,800.00 | | |
11/13/2012 | Nj Nicholas Jr | Director | Buy | 20,000 | $5.28 | $105,600.00 | | |
11/9/2012 | Nj Nicholas Jr | Director | Buy | 25,000 | $5.17 | $129,250.00 | | |
8/6/2012 | Ernest Mario | Director | Buy | 32,000 | $5.29 | $169,280.00 | | |
(Data available from 1/1/2013 forward)
Boston Scientific (NYSE BSX) News Headlines
Source: |
|
Boston Scientific (NYSE:BSX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Boston Scientific (NYSE:BSX) Income Statement, Balance Sheet and Cash Flow Statement
Boston Scientific (NYSE BSX) Stock Chart for Thursday, April, 19, 2018
Loading chart…